Gene and Cell Therapy · eu
Stargardt Disease Gene Therapy Moves Toward Phase 3: VeonGen Says It Has Reached Agreement With FDA on Trial Design
VG801 aims to restore gene function needed by the retina using two viral vectors. Vision improvements in 13 evaluable patients offer clues for further research; whether the treatment can deliver reliable, lasting benefits remains to be verified in a controlled trial that has yet to begin.
For patients with Stargardt disease, central vision may begin to decline gradually in childhood or adolescence, and there is currently no approved treatment. On November 5, VeonGen Therapeutics announced that it had reached agreement with the U.S. Food and Drug Administration (FDA) on the pivotal Phase 3 trial design and manufacturing elements for VG801, an investigational gene therapy targeting this inherited macular disease, providing clearer direction for the next stage of evaluation.
According to the company, the FDA meeting minutes cover the primary endpoint, study duration and control group design, as well as the use of existing clinical batches to supply the Phase 3 trial and some elements of the commercial manufacturing strategy. However, *Ophthalmology Management* noted that the announcement did not disclose specific details of the trial design; *BioPharm International* added that the planned enrollment had not been disclosed either, and the Phase 3 controlled study had not yet begun. This agreement represents progress in development planning and does not mean the therapy has been approved.
The core technology behind VG801 addresses the challenge that the ABCA4 gene exceeds the carrying capacity of a single adeno-associated virus (AAV) vector. It uses two vectors to deliver separate gene fragments, then uses messenger RNA trans-splicing to reassemble a message capable of producing a full-length, functional protein within retinal photoreceptor cells. This design aims to cover different disease-causing ABCA4 variants, but clinical evidence is still needed to establish whether it can achieve the intended effects in patients.
The current human data come from an ongoing first-in-human Phase 1/2 study in which 15 adults and children have received treatment across three dose groups. The company said that all 13 patients whose best-corrected visual acuity could be measured before treatment showed improvements from baseline at their Month 6 or Month 12 assessments. Of these, 11 gained at least 5 letters on the standard ETDRS visual acuity chart; among those 11, 7 gained at least 10 letters and 4 gained at least 15. These figures are not results from a common time point at which all participants had completed one year of follow-up.
Beyond visual acuity chart performance, the company also reported that data through Month 12 showed improvements in virtual reality vision testing and fixation stability measured by microperimetry, while retinal structure remained stable. However, the announcement described safety only in positive terms, without providing adverse event counts or comparative efficacy data, leaving readers unable to fully assess the treatment’s risks and benefits on that basis.
This early study is small, open-label and has no control group; *BioPharm International* noted that detailed results have also not yet been published in a peer-reviewed journal. The changes in vision therefore offer clues for further research but are not yet sufficient to establish VG801’s efficacy. More complete controlled data are still needed to determine whether the treatment caused the improvements, whether their magnitude is clinically meaningful and how long the effects may last.
How to measure whether patients actually see better is also part of the next stage of development. VeonGen is developing its virtual reality vision test through the FDA’s Rare Disease Endpoint Advancement Pilot Program as a functional vision measurement tool for Stargardt disease; this does not mean the tool has been selected as the Phase 3 primary endpoint. Public disclosure of the trial protocol, complete safety data and controlled study results will be needed to subject the therapy’s potential to more rigorous scrutiny.